Current position and use of intravenous immunoglobulins not only in intensive care medicine

Czech version

Authors: Průcha Miroslav ¹; Zazula Roman ²; Sedláčková Lenka ¹
Authors‘ workplace: Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha ¹; Anesteziologicko-resuscitační klinika 1. LF UK v Praze a Thomayerovy nemocnice, Praha ²
Published in: Anest. intenziv. Med., 23, 2012, č. 6, s. 300-306
Category: Review Article

Overview

Antibodies, or immunoglobulins, are one of the corner stones of innate immunity. Their main role is to maintain homeostasis: defence against infection and prevention of cancer and autoimmune diseases. Identification of the physiological role of antibodies stimulated the efforts to use them in therapy, which resulted in their use as intravenous immunoglobulins i.e. IVIG. There are two mechanisms of the therapeutic effects of IVIG: substitution and immunomodulation. The substitution effect takes place in primary immunodeficiencieswhich show impairment of antibody forming capacity. Their immunomodulatory properties are effective in autoimmune and tumor diseases. We present an overview of current knowledge of mechanisms of action of IVIG, their recognized indications in clinical practice, as well as their role and the ongoing debate about their benefits in the treatment of sepsis.

Keywords:
immunoglobulins – antibodies – innate imunity – IVIG – infection – autoimmunity

Sources

1. Lindenmann, J. Origin of the Terms ‚Antibody‘ and Antigen. Scand. J. Immunol., 1984, 19, p. 281–5.

2. Bednařik, J., Voháňka, S., Ehler, E., Amber, Z., Piťha, J., Vencovský, J., Litzman, J., Kořistek, Z., Suchý, M., Pata, M., Kožený, P. Standard pro léčbu pacientů s autoimunitními nervosvalovými onemocněními intravenoznim lidským imunoglobulinem a plazmaferézou. Česk. Slov. Neurol., 2010, 73, 106, s. 579–589.

3. Al-Herz, W., Bousfiha, A., Casanova, J. L., Chapel, H., Conley, M. E., Cunningham – Rundles, C., Etzioni, A., Fischer, A., Franco, J. L., Geha, R. S., Hammarström, L., Nonoyama, S., Notarangelo, L. D., Ochs, H. D., Puck, J. M.,Roifman, C. M., Seger, R., Tang, M. L. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front. Immunol., 2001, 2, p. 54–58.

4. Nimmerjahn, F., Ravetch, J. V. Fc gamma receptors as regulators of immune responses. Nat. Rev. Immunol., 2008, 8, p.34–47.

5. Orange, J. S., Hossny, E. M., Weiler, C. R., Ballow, M., Berger, M., Bonilla, F. A., Buckley, R., Chinen, J., El-Gamal, Y., Mazer, B. D., Nelson, R. P. Jr, Patel, D. D., Secord, E., Sorensen, R. U., Wasserman, R. L., Cunningham-Rundles, C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma, and Immunology. J. Allergy Clin. Immunol., 2006, 117, S525–S553.

6. Berger, M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr. Opin. Allergy Clin. Immunol., 2011, 11, p. 532–538.

7. Casadevall, A., Pirofski, L. A. A new synthesis for antibody-mediated immunity. Nat. Immunol., 2011, 13, p. 21–28.

8. Schwartz-Albiez, R., Monteiro, R. C., Rodriguez, M., Binder, C. J., Shoenfeld, Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin. Exp. Immunol., 2009, 158, Suppl 1, p. 43–50.

9. Negi, V. S., Elluru, S., Sibéril, S., Graff-Dubois, S., Mouthon, L., Kazatchkine, M. D., Lacroix-Desmazes, S., Bayry, J., Kaveri, S. V. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin.Immunol., 2007, 27, p. 233–245.

10. Tha-In, T., Metselaar, H. J., Tilanus, H. W. Intravenous immunoglobulins suppress T celll priming by modulating the bi-directional interaction between dendritic cells and natural killer cells. Blood, 2007, 110, p. 3253–3262.

11. Chong, B. H., Chong, J. J. H. IVIG immune inhibitory aktivity: APC is key. Blood, 2010, 115, p. 1663–1664.

12. Anthony, R. M., Kobayashi, T., Wermeling, F., Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature, 2011, 475, p. 110–113.

13. Smith, K. G., Clatworthy, M. R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol., 2010, 10, p. 328–343.

14. Kaneko, Y., Nimmerjahn, F., Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 2006, 313, p. 670–673.

15. Maddur, M. S., Sharma, M., Hegde, P., Lacroix-Desmazes, S., Kaveri, S. V., Bayry, J. Inhibitory Effect of IVIG on IL-17 Production by Th17 Cells is Independent of Anti-IL-17 Antibodies in the Immunoglobulin Preparations. J. Clin.Immunol., 2012, DOI: 10.1007/s10875-012-9752-6.

16. Laupland, K. B., Kirkpatrick, A. W., Delaney, A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit. Care Med., 2007, 35, p. 2686–2692.

17. Turgeon, A. F., Hutton, B., Fergusson, D. A., McIntyre, L., Tinmouth, A. A., Cameron, D. W., Hébert, P. C. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann. Intern. Med., 2007, 146, p. 193–201.

18. Kreymann, K. G., de Heer, G., Nierhaus, A., Kluge, S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit. Care Med., 2007, 35, p. 2677–2685.

19. INIS Collaborative Group, Brocklehurst, P., Farrell, B., King, A., Juszczak, E., Darlow, B., Haque, K., Salt, A., Stenson, B., Tarnow-Mordi, W. Treatment of neonatal sepsis with intravenous immune globulin. N. Engl. J. Med., 2011, 365, p. 1201–1211.

20. Werdan, K., Pilz, G., Bujdoso, O., Fraunberger, P., Neeser, G., Schmieder, R.E., Viell, B., Marget, W., Seewald, M., Walger, P., Stuttmann, R., Speichermann, N., Peckelsen, C.,Kurowski, V., Osterhues, H.H., Verner, L., Neumann, R., Müller-Werdan, U. Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit. Care Med., 2007, 35, p. 2693–2701.

21. Berlot, G., Vassallo, M. C., Busetto, N., Bianchi, M., Zornada, F., Rosato, I., Tartamella, F., Prisco, L., Bigotto, F., Bigolin, T., Ferluga, M., Batticci, I., Michelone, E.,Borelli, M., Viviani, M., Tomasini, A. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J. Crit. Care, 2012, 27, p. 167–171.

22. Darenberg, J., Söderquist, B., Normark, B. H., Norrby-Teglund, A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin. Infect. Dis., 2004, 38, p. 836–842.

23. Rankin, J. S., Oguntolu, O., Binford, R. S., Trochtenberg, D. S., Muhlbaier, L. H., Stratton, C. W. Management of immune dysfunction after adult cardiac surgery. J. Thorac. Cardiovasc. Surg., 2011, 142, p. 575–580.

24. Raithatha, A. H., Bryden, D. C. Use of intravenous immunoglobulin therapy in the treatment of septic shock, in particular severe invasive group A streptococcal disease. Indian J. Crit. Care Med., 2012, 16, p. 37–40.

25. Moitra, R., Beal, D. R., Belikoff, B. G., Remick, D. G. Presence of preexisting antibodies mediates survival in sepsis. Shock, 2012, 37, p. 56–62.

Labels

Anaesthesiology, Resuscitation and Inten Intensive Care Medicine

Acute warfarin reversal and the use of subarachnoid anaesthesia

Identification of potential organ donors after irreversible cardiac death (DCD) in the intensive care unit

Red Blood Cell Transfusion: A Clinical Practice Guideline from the AABB (American Association of Blood Banks)

Article was published in

Anaesthesiology and Intensive Care Medicine

2012 Issue 6